StockNews.AI

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

StockNews.AI • 2 days

IDEXHLSTMO
High Materiality8/10

Information

HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")...

Original source

AI Summary

VolitionRx Limited (VNRX) expands its Nu.Q® Vet Cancer test availability with new partnerships in the U.S. and Asia, enhancing access to canine cancer detection. The total addressable market for this test is estimated between $100-$150 million, indicating strong growth potential and improved outcomes for early cancer detection.

Sentiment Rationale

The increased accessibility of VNRX's innovative test is likely to drive revenue growth. Historical examples include diagnostics firms who saw stock price appreciation following product expansions.

Trading Thesis

VNRX appears bullish due to expanded market access and significant revenue potential.

Market-Moving

  • The new partnerships could significantly increase VNRX's revenues starting in 2026.
  • Total addressable market growth reflects escalating demand for canine cancer early detection.
  • Successful implementation in these markets may attract more veterinary partnerships.
  • Market reaction may be favorable due to the anticipated growth in revenue opportunities.

Key Facts

  • VNRX appoints new labs for its Nu.Q® Vet Cancer test in the U.S. and Asia.
  • Midwest Veterinary Laboratory will offer the test in all 50 U.S. states by February 2026.
  • Bioguard will provide the test via its certified lab in Taiwan and China.
  • Total Addressable Market for Nu.Q® Vet is projected at $100 million, rising to $150 million.
  • Earlier detection can significantly improve cancer treatment options for pet owners.

Companies Mentioned

  • Midwest Veterinary Laboratory (N/A): Expands VNRX’s reach in the U.S. veterinary market.
  • Bioguard (N/A): Opens up significant opportunities in Taiwan and China for VNRX.

Corporate Developments

This news falls under 'Corporate Developments' as it signifies key partnerships expanding VNRX's market presence. The enhancement of service offerings could strengthen brand recognition and demand in veterinary diagnostics.

VolitionRx (VNRX) Expands Availability of Nu.Q® Vet Cancer Test

Introduction

VolitionRx Limited (NYSE AMERICAN: VNRX), a leading multi-national epigenetics company, has announced the appointment of two new laboratory providers for its innovative Nu.Q® Vet Cancer test. This strategic move enhances access to this essential canine cancer detection tool in key markets, including the U.S. and Asia.

Details of the New Partnerships

The first provider, Midwest Veterinary Laboratory, is a full-service independent reference laboratory based in the U.S., which will make the Nu.Q® Vet Cancer test available to clients across all 50 states starting in February 2026. The second partner, Bioguard, is a global animal health diagnostics company. Bioguard has initiated offering the Nu.Q® Vet Cancer Test through its Animal Health Diagnostic Center, recognized as the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China.

Implications for Pet Health

Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, expressed enthusiasm about these partnerships. He stated, "We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the U.S. and Asia through these well-established reference labs." The incorporation of the Nu.Q® Canine Cancer Test in regular veterinary check-ups enables earlier cancer detection, empowering pet owners to make informed decisions regarding their pets' health.

Market Opportunity for Nu.Q® Vet

VolitionRx estimates that the Total Addressable Market (TAM) for canine cancer screening is approximately $100 million across the U.S., Europe, and Japan. With the addition of China, this figure could rise to nearly $150 million. This significant market opportunity positions VNRX well for growth in the veterinary diagnostics sector.

  • Midwest Veterinary Laboratory to offer Nu.Q® test across all 50 U.S. states.
  • Bioguard expands Nu.Q® test availability in Taiwan and China.
  • TAM for canine screening estimated to be around $100 million.
  • Potential growth to $150 million with inclusion of China.

About VolitionRx

VolitionRx is committed to advancing epigenetics to enhance health outcomes for both humans and animals. The company is focused on developing easy-to-use and cost-effective blood tests that support early disease detection and monitoring, including cancers and disorders associated with NETosis, such as sepsis. With R&D hubs located in Belgium and offices in the U.S. and London, VolitionRx is poised to lead in the diagnostics arena.

For media inquiries, please contact Louise Batchelor at Volition: [email protected], +44 (0)7557 774620.

Related News